Bayesian network meta-analysis for unordered categorical outcomes with incomplete data

Research Synthesis Methods

Volumn 5, Issue 2, 2014, Pages 162-185

  Schmid, Christopher H ^a   Trikalinos, Thomas A ^a   Olkin, Ingram ^b  

^a BROWN UNIVERSITY   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Correlated outcomes; Markov chain Monte Carlo; Missing data; Multinomial distribution; Multiple treatments meta analysis; Statin therapy

Indexed keywords

BAYES THEOREM; COMPUTER SIMULATION; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PROCEDURES; SAMPLE SIZE; STATISTICAL ANALYSIS; STATISTICAL MODEL;

BAYES THEOREM; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; META-ANALYSIS AS TOPIC; MODELS, STATISTICAL; OUTCOME ASSESSMENT (HEALTH CARE); SAMPLE SIZE;

EID: 84938692431     PISSN: 17592879     EISSN: 17592887     Source Type: Journal    
DOI: 10.1002/jrsm.1103     Document Type: Article

References (42)

1. Agresti A. 2002. Categorical Data Analysis. 2nd ed. New York: Wiley, 2002.
2. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. 2002. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to Pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288(23): 2998-3007.
3. Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA. 2006. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355(6): 549-559.
4. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. 2004. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364(9435): 685-696.
5. Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ. 2009. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med 28(14): 1861-1881.
6. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E. 2004. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292(11): 1307-1316.
7. Dias S, Sutton AJ, Ades AE, Welton NJ. 2013. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 33(5): 607-617.
8. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM, Jr. 1998. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279(20): 1615-1622.
9. Gelman A. 2006. Prior distributions for variance parameters in hierarchical models. Bayesian Analysis 1(3): 515-533.
10. Gelman A, Carlin JB, Stern HS, Rubin DB. 2004. Bayesian data analysis. 2nd ed. Chapman & Hall/CRC; 2004.
11. Heart Protection Study Collaborative Group. 2002. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326): 7-22.
12. Higgins JP, Whitehead A. 1996. Borrowing strength from external trials in a meta-analysis. Stat Med 15(24): 2733-2749.
13. Jackson D, Riley R, White IR. 2011. Multivariate meta-analysis: potential and promise. Stat Med 30(20): 2481-2498.
14. Jain M, Rosenberg M. 2012. Meta-analysis: lowering LDL-C levels using statins reduces major vascular events regardless of baseline risk. Ann Intern Med 157(8): JC4-2.
15. Kirkham JJ, Riley RD, Williamson PR. 2012. A multivariate meta-analysis approach for reducing the impact of outcome reporting bias in systematic reviews. Stat Med 31(20): 2179-2195.
16. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. 2006. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care 29(7): 1478-1485.
17. Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR. 2005. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med 24(15): 2401-2428.
18. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK. 2005. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352(14): 1425-1435.
19. Lu G, Ades A. 2006. Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc 101(474): 447-459.
20. Lu G, Ades A. 2009. Modeling between-trial variance structure in mixed treatment comparisons. Biostatistics 10(4): 792-805.
21. Marshall AW, Olkin I. Several types of failure: competing risks. Life Distributions. Structure of non-Parametric, Semi-Parametric and Parametric Families. New York: Springer; 2007.
22. Mavridis D, Salanti G. 2013. A practical introduction to multivariate meta-analysis. Stat Methods Med Res 22(2): 133-158.
23. Miller RG. 1981. Simulaneous Statistical Inference. 2nd ed. New York: Springer; 1981.
24. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y. 2006. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368(9542): 1155-1163.
25. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J. 2005. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294(19): 2437-2445.
26. Pinheiro JC, Bates DM. 1996. Unconstrained parameterizations for variance-covariance matrices. Stat Comput 6: 289-296.
27. Plummer M. 2003. JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling, Proceedings of the 3rd International Workshop on Distributed Statistical Computing (DSC 2003), March 20-22, Vienna, Austria. ISSN 1609-395X.
28. Plummer M. 2013. R package rjags [computer program]. Version 3.3.
29. Ribeiro RA, Ziegelmann PK, Duncan BB, Stella SF, da Costa Vieira JL, Restelatto LM, Moriguchi EH, Polanczyk CA. 2013. Impact of statin dose on major cardiovascular events: a mixed treatment comparison meta-analysis involving more than 175, 000 patients. Int J Cardiol 166(2): 431-439.
30. Riley RD. 2009. Multivariate meta-analysis: the effect of ignoring within-study correlation. J Royal Stat Soc A 172(4): 789-811.
31. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. 1996. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335(14): 1001-1009.
32. Scandinavian Simvastatin Survival Study Group. 1994. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934): 1383-1389.
33. Schmid CH, Landa M, Jafar TH, Giatras I, Karim T, Reddy M, Stark PC, Levey AS. 2003. Constructing a database of individual clinical trials for longitudinal analysis. Control Clin Trials 24(3): 324-340.
34. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. 2004. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs 64 Suppl 2: 43-60.
35. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG. 2002. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360(9346): 1623-1630.
36. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. 1995. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333(20): 1301-1307.
37. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. 1998. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339(19): 1349-1357.
38. The Post Coronary Artery Bypass Graft Trial Investigators. 1997. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 336(3): 153-162.
39. Trikalinos TA, Hoaglin DC, Schmid CH. 2013. Empirical and simulation-based comparison of univariate and multivariate meta-analysis for binary outcomes. Rockville (MD): Agency for Healthcare Research and Quality (US). Publication No. 13-EHC066-EF.
40. Trikalinos TA, Hoaglin DC, Schmid CH. 2013a. An empirical comparison of univariate and multivariate meta-analyses for categorical outcomes. Stat Med (in press).
41. Trikalinos TA, Olkin I. 2008. A method for the meta-analysis of mutually exclusive binary outcomes. Stat Med 27(21): 4279-4300.
42. Trikalinos TA, Olkin I. 2012. Meta-analysis of effect sizes reported at multiple time points: a multivariate approach. Clin Trials 9(5): 610-620.